Background-Available data on the clinical impact of new-onset left bundle branch block (LBBB) and permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) remains controversial. We aimed to evaluate the impact of (1) periprocedural new-onset LBBB or PPI post-TAVR on cardiac mortality and all-cause 1-year mortality and (2) new-onset LBBB on the need for PPI at 1-year follow-up. Methods and Results-We performed a systematic search from PubMed and EMBASE databases for studies reporting raw data on new-onset LBBB post-TAVR and the need for PPI or mortality at 1-year follow-up, or on 1-year mortality according to the need for periprocedural PPI post-TAVR. Data from 17 studies, including 4756 patients (8 studies) and 7032 patients (11 studies) for the evaluation of the impact of new-onset LBBB and periprocedural PPI post-TAVR were sourced, respectively (with 2 studies used for both outcomes). New-onset LBBB post-TAVR was associated with a higher risk of PPI (risk ratio [RR], 2.18; 95% confidence interval [CI], 1.28-3.70) and cardiac death (RR, 1.39; 95% CI, 1.04-1.86) during follow-up, as well with a tendency toward an increase in all-cause mortality (RR, 1.21; 95% CI, 0.98-1.50). Periprocedural PPI post-TAVR was not associated with any increased risk of all-cause mortality at 1 year (RR, 1.03; 95% CI, 0.9-1.18), yet a tendency toward a protective effect on cardiac death was observed (RR, 0.78; 95% CI, 0.60-1.03). Conclusions-New-onset LBBB post-TAVR is a marker of an increased risk of cardiac death and need for PPI at 1-year follow-up. The need for PPI early post-TAVR did not increase the risk of death. (Circ Cardiovasc Interv. 2016;9:e003635.
T ranscatheter aortic valve replacement (TAVR) is now an established treatment option for patients with aortic stenosis who are considered to be at high or prohibitive surgical risk. 1 Substantial improvements in technology, patient selection, and refined procedural techniques have provided the basis for TAVRs expansion toward treating a lower surgical risk aortic stenosis population. 2 However, the ocurrence of some periprocedural complications remain a concern.
Conduction disturbances and the need for permanent pacemaker implantation (PPI) frequently complicate TAVR. Importantly, the incidence of such complications has not changed significantly over time, with potentially a slightly rising incidence after the introduction of newer generation transcatheter valves. 3 Although the factors associated with conduction abnormalities and PPI post-TAVR are well described, 4 data on its clinical impact remain controversial. Studies evaluating the impact on mortality of new-onset left bundle branch block (LBBB) or need for periprocedural PPI post-TAVR have yielded conflicting results. [5] [6] [7] [8] The current systematic review and meta-analysis was thus aimed at assessing (1) the impact of new-onset LBBB post-TAVR on the need for PPI, all-cause death, and cardiac death and (2) the impact of periprocedural PPI post-TAVR on all-cause and cardiac death. Impact of Conduction Disturbances Post-TAVR
Methods

Search Strategy
A systematic review of the published data on new-onset LBBB in TAVR recipients and on the need for PPI after TAVR was conducted in accordance to the guidance and the reporting items specified the Preferred Reported Items for Systematic Reviews and MetaAnalysis (PRISMA) statement. 9 A computerized search was performed to identify all relevant studies from PubMed and EMBASE databases. MeSH terms used were: TAVR; heart block; pacemaker, artificial; electrode, implanted. Keywords used were: percutaneous aortic, transcatheter aortic, transcatheter aortic valve implantation, conduction, block, bundle, AV, and pacemaker. The search strategy is outlined in the Data Supplement. Databases were last accessed on May 31, 2015. Citations were screened at the title and abstract level and retrieved as full text if they reported on outcome after new-onset LBBB or the need of periprocedural PPI post-TAVR.
Study Selection
Studies were included if the following criteria applied: (1) original design and (2) reported data on mortality or the need of PPI during follow-up after new-onset LBBB post-TAVR, or reported data on mortality based on the need of periprocedural PPI after TAVR. When 2 similar studies were reported from the same institution or author, the most recent publication or the publication with most information was included in the analysis. Case reports or studies published in a non-English language were excluded.
Data Extraction
We extracted data of the patients and studies using a standardized data abstraction sheet. Two investigators (A.R. and O.A.J.A.) conducted the literature search, selection and data extraction in duplicate. Any discrepancies were resolved by consensus, when needed, with a third investigator (J.R.C.).
Outcome
The end points that were pooled for the group of new-onset LBBB post-TAVR patients were (1) risk of PPI at 1 year, (2) risk of cardiac mortality at 1 year, and (3) risk of all-cause mortality at 1 year. In addition, the following end points were pooled for the group of periprocedural PPI post-TAVR: (1) risk of cardiac mortality at 1 year and (2) risk of all-cause mortality at 1 year.
Statistical Analysis
Crude risk ratio (RR) was the principal summary measure. RRs were retrieved or directly calculated with the corresponding 95% confidence interval (CI) for each end point and entered into the primary analysis. Consistency across the studies was assessed with the I 2 index. 10 For variables exhibiting mild heterogeneity (I 2 ≤25%), pooled estimates were derived with the Mantel-Haenszel fixedeffects models. For variables exhibiting significant heterogeneity, pooled estimates were derived using the DerSimonian and Laird random effects model. 11 To assess the potential effect of publication bias, we inspected funnel plots for asymmetry and used the Harbord test 12 as a formal statistical test. An exploratory metaregression analysis was performed to examine a potential association between end points with the type of valve implanted during the procedure. Descriptive characteristics are presented as mean SD or median (interquartile range) when appropriate for continuous variables and frequencies and percentages for categorical variables. Statistical analyses were performed in STATA software (version 13.0, STATA Corp, College Station, TX) and RevMan (version 5.3.5, Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration).
WHAT IS KNOWN
• Conduction disturbances and the need for PPI are frequent complications of TAVR, data on its clinical impact remain highly controversial, and studies evaluating the effect on mortality of new-onset LBBB or need for periprocedural PPI post-TAVR have yielded conflicting results.
WHAT THE STUDY ADDS
• Our study showed an increased risk of PPI and cardiac death at 1-year follow-up in those patients with new-onset LBBB post-TAVR and no impact of PPI post-TAVR on cardiac or all-cause death at follow-up. 
Results
A PubMed search identified 693 reports, whereas an EMBASE search uncovered 1311, yielding 978 records which were reviewed at the title and abstract level after exclusion of duplicates. Of those, 179 articles were selected and assessed for eligibility at full-text level. Five studies (5612 patients) were excluded from the quantitative synthesis because of missing data on the primary end point, despite reporting different outcomes based on the presence of new-onset LBBB or the need of PPI post-TAVR. [13] [14] [15] [16] [17] Finally, 17 studies were included for assessing primary end points, and of those, 8 studies were deemed eligible for assessing the outcome of patients with new-onset LBBB post-TAVR, 5, 6, [18] [19] [20] [21] [22] [23] [24] whereas 11 studies were deemed eligible for assessing the outcome of patients with PPI post-TAVR. 5, 7, 8, [17] [18] [19] [25] [26] [27] [28] [29] [30] [31] Figure 1 shows the PRISMA flow diagram. Quantitative synthesis was performed on 4756 patients to assess the clinical impact of new-onset LBBB post-TAVR and on 7032 patients to assess the clinical impact of periprocedural PPI post-TAVR.
Impact of New-Onset LBBB After TAVR on the Risk of Death and PPI
Eight studies were used to evaluate the impact of new-onset LBBB post-TAVR on 3 different end points: (1) 1-year risk of PPI, (2) 1-year cardiac mortality, and (3) 1-year all-cause mortality. Among the selected studies, the study of Nazif et al 22 was unique in that it included patients from a randomized clinical trial (The Placement of Aortic Transcatheter Valve [PARTNER trial]), although these data were not exclusive because it also included patients from a registry. All remaining studies were observational registries. With the exception of the study from Houthuizen et al, 21 new-onset LBBB was defined as appearing post-TAVR, and remaining until hospital discharge. The rate of new-onset LBBB at discharge ranged from 13.3% to 37%. Despite this relative consistency in the inclusion criteria, exclusion criteria varied significantly between studies. In regard to ECG analyses, Nazif et al 22 were the only investigators who used an independent core laboratory for defining LBBB. In addition, Urena et al 20 extended the follow-up period beyond 1 year (median follow-up 13 months, interquartile range: 3-27 months), consequently out of 29 events from the previous study were included in the current meta-analysis. Study and population characteristics are shown in Tables 1 and 2 .
The risk of PPI after TAVR in patients with new-onset LBBB was estimated by analyzing 5 studies (3363 patients with LBBB; self-expandable valve [SEV] 28.4% versus balloon-expandable valve [BEV] 71.6%). The rate of PPI 1 year post-TAVR was 17.5%, (range, 5.2%-35.9%), including 55 patients who required PPI before discharge from the analysis of Urena et al, 20 and 61 patients who required PPI within 48 hours after TAVR from the analysis of Testa et al. 6 The rate of advanced atrioventricular block (AVB, as an indication for PPI during follow-up) varied from 78% to 89% in patients with new-onset LBBB, and in patients without LBBB the range was between 22.4% and 80% (Table I in Figure 2B ). Heterogeneity between studies was moderate (I 2 =32%) and the Harbord test did not reveal any significant asymmetry (P=0.189). The pooled risk did not vary significantly when omitting studies with <200 patients in a sensitivity analysis (RR, 1.43; 95% CI, 1.04-1.96; P=0.03). Because of a limitation in the number of included studies, we did not perform a meta-regression analysis to evaluate the association between the risk of cardiac death and the type of valve.
The risk of 1-year all-cause death was evaluated from 8 studies 6, [18] [19] [20] [21] [22] [23] 32 that included 4756 patients (SEV 36.5% versus BEV 63.5%). The overall pooled RR was 1.21 (95% CI, 0.98-1.50; P=0.07; Figure 2C ). Inconsistency across studies was moderate (I 2 =50%), and no asymmetry was detected with the Harbord test (P=0.757). The pooled risk did not vary significantly when omitting studies with <200 patients in a sensitivity analysis (RR, 
Impact of Periprocedural PPI After TAVR on the Risk of Death
Eleven studies were used to evaluate the impact of periprocedural PPI after TAVR on mortality. All studies except for Nazif et al 7 were observational in nature. Criteria for PPI were described in 8 studies (61%). Five studies used either the American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rythm Society (HRS) 8, 18 or the European Society of Cardiology (ESC) guidelines. 19, 29, 31 Complete AVB was the most frequent indication for PPI after TAVR, with the exception of Pereira et al, 31 who reported a higher rate of Mobitz II second degree AVB than complete AVB (42% versus 21%). Dual-chamber pacemaker was the most frequently implanted device. With the exception of 2 studies, the rate of right ventricular stimulation was not reported. In the analysis of the PARTNER trial and registry, the authors reported that 50.5% of patients who required PPI had evidence of right ventricular pacing in the ECG performed 1-year follow-up. 7 Similarly, Pereira et al 31 reported a cumulative ventricular pacing requirement of 49.5% in the pacemaker interrogation after 12 months of the procedure. Characteristics of the studies and population are shown in Tables 3 and 4 . Detailed information about the indications for PPI and type of device can be found in the Table II in the Data Supplement.
The risk of 1-year all-cause death was pooled from 11 studies 5, 7, 8, 19, [25] [26] [27] [28] [29] [30] [31] that included 7032 patients. The RR was 1.03 (95% CI, 0.9-1.18; P=0.64; Figure 3A) . Heterogeneity between studies was not significant (I 2 =0%). No asymmetry ). No association was found between the type of valve and the risk of 1-year all-cause death on a random effects meta-regression analysis (P=0.305).
The risk of 1-year cardiac death was pooled from 3 studies 7, 8, 22 (n=4362). A borderline, nonsignificant, potentially protective effect of PPI on cardiac death was observed (RR, 0.77; 95% CI, 0.58-1.01; P=0.06). Heterogeneity across studies was low (I 2 =0%; Figure 3B ). No asymmetry was observed with the Harbord test (P=0.235). Because of a limitation in the number of included studies for this end point, we did not perform a meta-regression analysis to evaluate the association between cardiac death and the type of valve.
Discussion
The results of the present meta-analysis can be summarized as follows: (1) new-onset LBBB post-TAVR seems to significantly increase the risk of cardiac death and need for PPI at 1-year follow-up and (2) periprocedural PPI seemed not to associate with an increased risk of death (global or cardiac) within the year after TAVR.
New conduction disturbances represent a frequent post-TAVR complication. The reported rate of new-onset LBBB 
Impact of Conduction Disturbances Post-TAVR
post-TAVR is ≈27%, ranging from 9% to 65% after the self-expanding CoreValve system implantation, or ≈11% (4%-18%) postballoon-expandable Edwards valve implantation. 33 With reference to PPI, the reported rate of PPI after TAVR is ≈17% (range 18%-49%) after self-expanding CoreValve implantation and ≈6% (0%-12%) after balloonexpandable Edwards valve implantation. Despite the fact that the incidence of these conduction disturbances and PPI has slowly decreased over time, 3 this effect seems to be limited to patients receiving a SEV and is partially related to significant reductions in valve implantation depths and improvement in the delivery systems. 34 Furthermore, the incidence of major periprocedural complications post-TAVR has decreased dramatically in recent times after the adoption of new valve technologies. However, early results show a lack of reduction, or even an increase in the rate of conduction system disturbances associated with these so-called new-generation valves. 3 Specifically, an increase rate of PPI has been reported with the use of the third-generation balloon-expandable Edwards valve when compared with the previous Edward valve generations. This finding has been attributed to the incorporation of an external fabric cuff in the inferior part of the valve intended to minimize paravalvular leak. A higher (more aortic) valve depth implantation of this new-generation valve might help in preventing the higher risk of PPI. 35 Furthermore, no significant decreases in the incidence of new conduction system disturbances is expected with the novel generatino devices, as no additional features have been specifically designed to reduce the risk of these conduction system-based complications.
Impact of New-Onset LBBB on the Risk of PPI and Death
A higher rate of PPI at 1-year follow-up among patients with new-onset LBBB was observed in the present meta-analysis. The rate of PPI after TAVR across the various studies used in the present meta-analysis was relatively low, and this can be explained by the frequent use of a BEV. The increased risk of complete AVB with SEV has been previously described. 4 The continuous radial force of the nitinol stent in the SEV and the potential for deeper implantation leading to persistent AV node and LBB mechanical compression and injury have been postulated to explain these between-valve differences in PPI rates. Another possible factor that could partially explain a higher risk of PPI was a lower threshold for treating patients with new-onset LBBB. However, when evaluating the reasons for PPI in patients with new-onset LBBB post-TAVR, close to 80% of the patients, who underwent PPI with ambulatory ECG monitoring up to 3 years could help us to identify the subgroup of patients that could progress from LBBB to complete AV block after TAVR, requiring PPI during follow-up.
In our study, patients with new-onset LBBB had a higher risk of cardiac death after 1-year of follow-up. The increased risk of death could be attributed to 3 physiopathological mechanisms: (1) the increased risk of ventricular arrhythmias in patients with reduced ejection fraction and ventricular dyssynchrony or (2) the progression to advanced AVB or (3) the combination of LBBB-induced intraventricular dyssynchrony and subsequent systolic dysfunction, followed by clinical heart failure.
The presence of LBBB is known to be a marker of poor long-term survival in the general population 36 and in patients with cardiac disease. 37 LBBB produces an intraventricular dyssynchrony that results in deterioration of left ventricle (LV) systolic and diastolic function, 38 it is also known that the effect of LBBB is dominant over the presence of cardiomyopathy, on the deterioration of LV function. 39 This negative effect on ventricular function has been observed also in patients that develop LBBB post-TAVR. The consequences of intraventricular dyssynchrony are not limited to the mechanical function of the ventricle, as they can be an important factor in ventricular arrhythmogenesis. Kutyifa et al 40 demonstrated that improved synchrony might translate into a reduction of ventricular arrhythmic events in patients with LBBB by a more homogeneous LV mechanical activation followed by electric resynchronization per se. In addition, constant mechanical compression of the conduction system by the transcatheter valve could be responsible for the progression of LBBB to complete AV block, 41 increasing the risk of sudden cardiac death in patients without a permanent pacemaker. Also, new-onset persistent LBBB after TAVR may be a marker of greater vulnerability toward the occurrence and progression of conduction disturbances irrespective of the procedure.
Although there was an increased risk of cardiac death associated with new-onset LBBB post-TAVR, there was, however, no difference in the risk of all-cause death. Several points need to be considered to explain these findings. The population included in the studies had a high baseline risk morbidity and mortality risk, and this high prevalence of severe noncardiac comorbidities could have translated into high incidence of death from noncardiac causes in both groups, and the effect of LBBB could have been masked. We decided to use the RRs as a risk measure, although some studies reported the adjusted hazard ratio. The decision was based on the fact that the number of patients included in studies who reported the adjusted hazard ratio was limited, and that the covariables used for the adjustment were not comparable between studies. Despite this, there was not a higher risk of all-cause death in patients with new-onset LBBB after performing a meta-analysis of the studies that reported an adjusted hazard ratio. The present meta-analysis failed to show an increased risk of death in patients who received a PPI after TAVR. In fact, there was a tendency toward a protective effect from cardiac death in the year after the procedure. As previously discussed, patients with new-onset LBBB post-TAVR may have harbored a higher risk of cardiac death partially because of progression toward complete AVB and sudden death, 36 which could have been prevented by PPI. It is known that the need for pacing increases the risk of heart failure and late mortality. 42 This detrimental impact on heart failure and mortality depend on the cumulative time of ventricular pacing. However, information on the requirement of ventricular pacing was available only from 2 of 11 studies included in the present meta-analysis. In both of these studies, approximately half of the patients did not require ventricular pacing after 1-year of follow-up. The percentage of ventricular pacing is similar to those reported in other studies who were not included in the present analysis. 16 This suggests that in a significant proportion of patients complete AVB present on TAVR at discharge resolved over time, as complete AVB was the most frequent indication for PPI. It has been further suggested that the deleterious impact of PPI might differ between different subgroups of patients. Although the majority of patients with a standard indication for PPI remain clinically stable over time, patients with low LV ejection fraction and LBBB notionally possess a higher risk of hospitalization or death because of heart failure. 43 Thus, the deleterious effect of ventricular pacing over time in patients undergoing TAVR could be masked by the severity of comorbidities and concomitant structural heart disease, as well as the immediate hemodynamic improvement after valve implantation. 8 However, it is also known that after an early increase in LV ejection fraction post-TAVR, PPI implantation is associated with reduced LV ejection fraction at 6 months, 8 although this lack of improvement does not seem to affect clinical outcomes after 2 years of follow-up. 27 Finally, a much longer time period may be necessary to detect a negative effect of PPI on cardiovascular and global outcomes. 44 
Study Limitations
Several limitations of the present meta-analysis warrant consideration. Our findings derive mainly from observational studies with retrospective analysis. The pooled analysis for each end point was obtained from a limited number of studies because of a high variability when reporting clinical outcomes associated with the exposure to PPI or new-onset LBBB after TAVR. Heterogeneity across studies was high when we analyzed the risk of death and PPI associated with new-onset LBBB post-TAVR. However, the results remained similar after a sensitivity analysis that excluded smaller studies or with the use of a fixed-effects model.
In conclusion, the present meta-analysis provides evidence that the development of LBBB post-TAVR correlates Figure 3 . Risk of cardiac death and all-cause death in patients with periprocedural permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR). A, Risk of all-cause death according to the need for periprocedural PPI after TAVR. 5, 7, 8, 19, [25] [26] [27] [28] [29] 31 B, Risk of cardiac death according to the need for periprocedural PPI after TAVR. 7, 8, 26 CI indicates confidence interval; and RR, risk ratio. Impact of Conduction Disturbances Post-TAVR with a greater risk of cardiac death and need for PPI within the year after the procedure. However, the need for PPI post procedurally had no impact on cardiac and all-cause death rates, and a trend toward a protective effect on cardiac death was observed. Conduction disturbances post-TAVR remains an ongoing problem because of its high incidence and negative clinical impact. Further efforts are important to identify the factors associated with the progression of conduction disturbances to appropriately risk stratify patients and provide an optimal treatment.
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